Wednesday, 12 Dec 2018

You are here

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.

COAST-W is a multicenter, randomized, double-blind, placebo-controlled 16-week study of the efficacy and safety of ixekizumab in active AS patients who were TNFi-IR.  Patients were treated with 80 mg of Taltz SC either every two weeks or every four weeks (following a 80 mg or 160 mg starting dose at Week 0), or placebo.  The primary efficacy endpoint was the proportion of patients at 16 weeks who achieved ASAS40 response.

The Taltz development program (COAST) in axial SpA (AS) includes the three different trials COAST-V (bDMARD-naïve), COAST-W (TNFi experienced), and COAST-X (non-radiographic axSpA who are bDMARD-naïve) studies . A long-term extension study will study patients for an additional two years. 

COAST-W trial showed superior (ASAS40) responses at 16 weeks compared to placebo treated patients. The incidence of serious adverse events was similar with Taltz compared with placebo. 

Ixekizumab is currently FDA approved for the treatment of adults with active psoriatic arthritis and adults with moderate-to-severe plaque psoriasis.

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.

Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis

Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time its filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis or ankylosing spondylitis.

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Doubling Down on IL-17 In Psoriatic Arthritis

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

Updates on Psoriatic Arthritis at ACR 2018

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.